Linden Lake Ventures
Linden Lake Ventures is a Bethesda, Maryland-based early-stage biotechnology-focused venture capital firm founded in 2019. It invests in biotechnology companies developing molecular medicines and seeks to support pre-clinical and phase I technologies, with an emphasis on oncology, immunology, hepatology, cardiovascular, respiratory, neurology, and orphan diseases. The firm takes a hands-on approach to help portfolio companies advance their programs.
2 past transactions
CrossBridge Bio
Seed Round in 2024
CrossBridge Bio is a biotechnology company specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. It innovates through its stable dual linker payload technology, aiming to enhance efficacy and safety profiles.
Vesigen Therapeutics
Series A in 2020
Vesigen Therapeutics, established in 2020 and based in Cambridge, Massachusetts, specializes in developing innovative therapeutic products. The company's core technology, ARMMs (ARRDC1 Mediated Microvesicles), facilitates the delivery of various payloads such as RNAs, proteins, and gene-editing complexes directly into the cytoplasm of target cells. This approach overcomes intracellular delivery barriers, expanding the scope of treatable conditions and enabling new therapies for unmet medical needs.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.